dorzolamide and Pain

We compared latanoprost monotherapy therapy with timolol/ dorzolamide in patients with primary open-angle glaucoma to evaluate the effects on intraocular pressure (IOP) and occurrence of adverse events. IOP and topical side effects were evaluated at the beginning, first, and third months. Mean IOP was decreased at the third month. The most common side effect was hyperemia (43.6%). We concluded that latanoprost reduces IOP better than fixed combination and its topical side effects are tolerable.

Topics: Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Eye Color; Eyelashes; Female; Glaucoma, Open-Angle; Humans; Hyperemia; Intraocular Pressure; Latanoprost; Male; Middle Aged; Pain; Prostaglandins F, Synthetic; Pruritus; Sulfonamides; Thiophenes; Timolol

To compare ocular tolerability of dorzolamide 2%, brinzolamide 1%, and placebo given three times daily.. A prospective, double-masked, three-centre, crossover comparison in which 25 ocular hypertensive or primary-open angle glaucoma subjects were randomized to receive dorzolamide, brinzolamide, or placebo three times daily for 3 days. Intraocular pressure, visual acuity, a visual analogue scale, and ocular and systemic symptom queries were completed at the end of each period.. After chronic dosing, there was a significant difference in ocular pain on the visual analogue scale among the groups at the 10-s postinstillation time point with dorzolamide having the highest level (22.5+/-28.9) compared to brinzolamide (5.0+/-8.7) or placebo (3.2+/-10.4) (P=0.0006). No differences between groups were observed preinstillation nor following dosing at 3 or 10-min postinstillation. On the initial instillation, the 10-s postinstillation pain was rated as 43.3+/-77.1, which was significantly higher than after chronic dosing (P=0.017). On the ocular symptom query, dorzolamide had the highest incidence of burning/stinging and redness compared to the other groups, but was generally characterized as mild. There were no significant differences in the visual acuity at any time point.. This study suggests that subjects treated with dorzolamide suffer more ocular pain upon instillation compared to brinzolamide or placebo. However, pain symptoms are fewer following chronic dosing and are generally characterized as mild.

Topics: Adult; Aged; Antihypertensive Agents; Carbonic Anhydrase Inhibitors; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; Glaucoma, Open-Angle; Humans; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Pain; Pain Measurement; Prospective Studies; Severity of Illness Index; Sulfonamides; Thiazines; Thiophenes

To characterize and compare the ocular comfort and symptoms of dorzolamide and tear-replacement drops (placebo) in healthy volunteers.. Subjects were randomized in a double-masked fashion to receive each medicine for 6 days twice daily. Patients used a visual analog scale to assess the quality and intensity of pain temporally after initial (acute) dosing and after 6 days of chronic dosing. The visual analog scale, an objective measure of pain, allows a subject to grade their perceived intensity of pain on a line between 0 and 100 mm.. Of 28 subjects enrolled in the study, 27 completed the protocol (1 subject was lost to follow-up). Dorzolamide demonstrated statistically greater peak ocular pain (21.4 +/- 22.3 mm) compared with placebo (1.9 +/- 4.4 mm) (P<0.0001) after chronic dosing. Time of mean peak pain for dorzolamide products was 15 seconds after dosing. The pain was statistically greater with dorzolamide compared with placebo for 50 seconds after dosing. On average the discomfort associated with dorzolamide lasted 38.9 +/- 17.9 seconds after dosing. The average pain per second for the first minute was 7.1 +/- 10.1 mm for dorzolamide. No differences in pain intensity were observed after acute and chronic dosing. The discomfort with dorzolamide was characterized after chronic dosing as "burning" (14.8 +/- 25.0 mm) and was associated with tearing (1.9 +/- 5.2 mm).. Dorzolamide caused more ocular pain after instillation than placebo. However, the pain was characterized as mild and quickly resolved.

Topics: Acute Disease; Adult; Carbonic Anhydrase Inhibitors; Chronic Disease; Double-Blind Method; Eye Diseases; Female; Humans; Male; Ophthalmic Solutions; Pain; Pain Measurement; Sulfonamides; Thiophenes; Time Factors

To report a case of glaucomatocyclitic crisis (Posner-Schlossman syndrome) in a child.. Case report. A 13-year-old boy presented with decreased vision, photophobia, halos, and pain in the right eye.. Findings in this child were consistent with a diagnosis of Posner-Schlossman syndrome.. Glaucomatocyclitic crisis can occur in a child and must be included in the differential diagnosis of uveitis and glaucoma in pediatric patients.

Topics: Adolescent; Clonidine; Corneal Edema; Diagnosis, Differential; Drug Therapy, Combination; Glaucoma; Humans; Intraocular Pressure; Male; Pain; Prednisolone; Sulfonamides; Syndrome; Thiophenes; Timolol; Uveitis, Intermediate; Vision Disorders; Visual Acuity